artemether:lumefantrine (2.5 mg:30 mg)
Phase 2/3Terminated 0 watching 0 views this week📈 Rising
65
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Plasmodium Falciparum Malaria
Conditions
Plasmodium Falciparum Malaria
Trial Timeline
Dec 21, 2020 → May 10, 2024
NCT ID
NCT04300309About artemether:lumefantrine (2.5 mg:30 mg)
artemether:lumefantrine (2.5 mg:30 mg) is a phase 2/3 stage product being developed by Novartis for Plasmodium Falciparum Malaria. The current trial status is terminated. This product is registered under clinical trial identifier NCT04300309. Target conditions include Plasmodium Falciparum Malaria.
Hype Score Breakdown
Clinical
22
Activity
15
Company
10
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04300309 | Phase 2/3 | Terminated |
Competing Products
13 competing products in Plasmodium Falciparum Malaria
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| KLU156 + Coartem | Novartis | Phase 3 | 77 |
| INE963 | Novartis | Phase 2 | 52 |
| KAE609 + Piperaquine Phosphate | Novartis | Phase 1 | 33 |
| KAE609 + SoC (Coartem) + KLU156 | Novartis | Phase 2 | 52 |
| KAF156 + Coartem + Lumefantrine Solid Dispersion Formulation | Novartis | Phase 2 | 52 |
| Artemether-lumefantrine | Novartis | Phase 3 | 77 |
| INE963 + KAE609 (Cipargamin) + SoC (Coartem) + KLU156 | Novartis | Phase 2 | 52 |
| KAF156 + LUM-SDF + Coartem | Novartis | Phase 2 | 52 |
| Azithromycin/Chloroquine + Sulfadoxine-Pyrimethamine/Chloroquine | Pfizer | Phase 2/3 | 64 |
| Ferroquine (SSR97193) + Placebo + artesunate | Sanofi | Phase 2 | 51 |
| Ferroquine SSR97193 + Artefenomel | Sanofi | Phase 2 | 51 |
| Artefenomel (OZ439) + Ferroquine (SSR97193) | Sanofi | Phase 2 | 51 |
| Meplazumab for Injection + Sterile normal saline (0.9%) | Pacific Biosciences | Phase 1 | 25 |